Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02357225 · ClinicalTrials.gov registry record · Early Phase 1
A Pilot Study of Pyridostigmine in Pompe Disease
A Early Phase 1 study, sponsored by University of Florida.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT02357225: Clinical Trial Early Phase 1 study, sponsored by University of Florida.
NCT02357225 is a Early Phase 1 study that was terminated before completion, run by University of Florida. The registered enrollment target is 2 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02357225, a Early Phase 1 study, was terminated before completion, sponsored by University of Florida.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
Pyridostigmine is an acetylcholinesterase inhibitor, which degrades acetylcholine at the neuromuscular junction. Based on recent studies, pyridostigmine may be an effective adjuvant treatment for people with Pompe disease, as it increases the functional impact of this neurotransmitter. Hypothesis: the use of pyridostigmine in Pompe disease will improve transmission of acetylcholine across the neuromuscular junction, skeletal muscle function, respiratory function, and quality of life.
Primary Outcome
Quantitative muscle testing and the 6 Minute Walk Test will be used to evaluate skeletal muscle function.
Interventions
- DRUG Pyridostigmine Bromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-08 |
| Est. Completion | 2018-01-01 |
| Phase | Early Phase 1 |
Why NCT02357225 stopped before completion
NCT02357225 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Pyridostigmine Bromide is the first listed.
NCT02357225 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02357225 about?
NCT02357225 is a clinical study titled "A Pilot Study of Pyridostigmine in Pompe Disease". Pyridostigmine is an acetylcholinesterase inhibitor, which degrades acetylcholine at the neuromuscular junction. Based on recent studies, pyridostigmine may be an effective adjuvant treatment for people with Pompe disease, as it increases the functional impact of this neurotransmitter. Hypothesis: ...
What is the current status of trial NCT02357225?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2015-08. Estimated completion is 2018-01-01.
What interventions are being tested in trial NCT02357225?
The interventions under investigation include: Pyridostigmine Bromide (DRUG).
Who is sponsoring clinical trial NCT02357225?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02357225's enrollment target sits among peer trials
2 1973rd of 2000 higher than 16 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia